The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | MRD-guided therapy for myeloma
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses measurable residual disease (MRD)-guided therapy and it’s implications for the treatment of multiple myeloma. Dr Landgren explains that MRD negativity has been associated with both progression-free survival and overall survival and may be a viable tool to assess and accordingly alter the intensity of therapies. Although further research into the role of MRD-guided therapy is required, utilizing MRD negativity in this way seems to be a promising route for therapy optimization. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
